Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 12, Issue 2, 2003, Pages 103-113

  Baron, Andre T ^a   Cora, Elsa M ^c   Lafky, Jacqueline M ^a   Boardman, Cecelia H ^e   Buenafe, Marites C ^b   Rademaker, Alfred ^d   Liu, Dachao ^d   Fishman, David A ^d   Podratz, Karl C ^b   Maihle, Nita J ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC ROCHESTER   (United States)

^c UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^d NORTHWESTERN UNIVERSITY   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY;

ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER RISK; CANCER SCREENING; CANCER STAGING; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE MARKER; EARLY DIAGNOSIS; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MENOPAUSE; OVARY CANCER; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; GENES, ERBB-1; HUMANS; MASS SCREENING; MENOPAUSE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REFERENCE VALUES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SOLUBILITY; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; WOMEN'S HEALTH;

EID: 12244261580     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. Jemal, A., Thomas, A., Murray, T., and Thun, M. Cancer statistics, 2002. CA Cancer J. Clin., 52: 23-47, 2002.
2. Berek, J. S., and Bast, R. C., Jr. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer (Phila.), 76: 2092-2096, 1995.
3. Karlan, B. Y. Screening for ovarian cancer: what are the optimal surrogate endpoints for clinical trials? J. Cell. Biochem., 23(Suppl.): 227-232, 1995.
4. Ozols, R. F., Rubin, S. C., Thomas, G., and Robboy, S. Epithelial ovarian cancer. In: W. J. Hoskins, C. A. Perez, and R. C. Young (eds.), Principles and Practice of Gynecol. Oncol., pp. 919-986. Philadelphia, PA: Lippincott-Raven Publishers, 1997.
5. Goff, B. A., Mandel, L., Muntz, H. G., and Melancon, C. H. Ovarian carcinoma diagnosis. Cancer (Phila.), 89: 2068-2075, 2000.
6. La Vecchia, C. Epidemiology of ovarian cancer: a summary review. Eur. J. Cancer Prev., 10: 125-129, 2001.
7. Runnebaum, I. B., and Stickeler, E. Epidemiological and molecular aspects of ovarian cancer risk. J. Cancer Res. Clin. Oncol., 127: 73-79, 2001.
8. Young, R. C., Walton, L. A., Ellenberg, S. S., Homesley, H. D., Wilbanks, G. D., Decker, D. G., Miller, A., Park, R., and Major, F., Jr. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N. Engl. J. Med., 322: 1021-1027, 1990.
9. Urban, N. Screening for ovarian cancer. We now need a definitive randomised trial. Br. Med. J., 319: 1317-1318, 1999.
10. Young, R. C., Decker, D. G., Wharton, J. T., Piver, M. S., Sindelar, W. F., Edwards, B. K., and Smith, J. P. Staging laparotomy in early ovarian cancer. JAMA, 250: 3072-3076, 1983.
11. McGowan, L. Patterns of care in carcinoma of the ovary. Cancer (Phila.), 71: 628-633, 1993.
12. Srivastava, S., and Kramer, B. S. Early detection cancer research network. Lab. Investig., 80: 1147-1148, 2000.
13. Fishman, D. A., Cohen, L., Bozorgi, K., Singh, D., O'Donnell, A., Donnelly, M., O'Rourke, J., Pfeifer, K., Lu, T., Maihle, N. J., Baron, A. T., Stack, M. S., Lurain, J., and Schwartz, P. E. The scientific basis for the accurate detection of early stage epithelial ovarian carcinoma, part 1. The Female Patient, 27: 11-15. 2002.
14. Brandt-Rauf, P. W. The c-erbB transmembrane growth factor receptors as serum biomarkers in human cancer studies. Mutat. Res., 333: 203-208, 1995.
15. McKenzie, S. J. Diagnostic utility of oncogenes and their products in human cancer. Biochim. Biophys. Acta. 1072: 193-214, 1991.
16. Lafky, J. M., Greenewood, T. M., Baron, A. T., Boardman, C. H., Cora, E. M., and Maihle, N. J. Soluble ErbB receptors (sEGFR/sErbBs): serum biomarker in breast and ovarian cancer. In: E. P. Diamandis, H. A. Fritsche, H. Lilja, D. W. Chan, and M. K. Schwartz (eds.), Tumor Markers: Physiology, Pathobiology, Technology and Clinical Applications, pp. 427-431. Washington, D. C.: American Association for Clinical Chemistry, Inc., 2002.
17. Maihle, N. J., Baron, A. T., Barrette, B. A., Boardman, C. H., Christensen, T. A., Cora, E. M., Faupel-Badger, J. M., Greenewood, T., Juneja, S. C., Lafky, J. M., Lee, H., Reiter, J. L., and Podratz, K. C. EGF/ErbB receptor family in ovarian cancer. In: M. S. Stack and D. A. Fishman (eds.), Ovarian Cancer, pp. 247-258. Boston, MA: Kluwer Academic Publishers, 2002.
18. Zabrecky, J. R., Lam, T., McKenzie, S. J., and Camey, W. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells. SK-BR-3. J. Biol. Chem., 266: 1716-1720, 1991.
19. Pupa, S. M., Menard, S., Morelli, D., Pozzi, B., De Palo, G., and Colnaghi, M. I. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene, 8: 2917-2923, 1993.
20. Petch, L. A., Harris, J., Raymond, V. W., Blasband, A., Lee, D. C., and Earp, H. S. A truncated, secreted form of the epidermal growth factor receptor is encoded by an alternatively spliced transcript in normal rat tissue. Mol. Cell. Biol., 10: 2973-2982, 1990.
21. Ilekis, J., Stark, B. C., and Benveniste, R. Expression of epidermal growth factor receptors at the mRNA and cell membrane levels in first trimester and term human placentae. In: R. K. Miller and H. A. Thiede (eds.), Molecular Biology and Cell Regulation of the Placenta, Trophoblast Research 5, pp. 103-117. New York, NY: Plenum, 1991.
22. Ilekis, J. V., Stark, B. C., and Scoccia, B. Possible role of variant RNA transcripts in the regulation of epidermal growth factor receptor expression in human placenta. Mol. Reprod. Dev., 41: 149-156, 1995.
23. Maihle, N. J., Flickinger, T. W., Raines, M. A., Sanders, M. L., and Kung, H-J. Native avian c-erbB gene expresses a secreted protein product corresponding to the ligand-binding domain of the receptor. Proc. Natl. Acad. Sci. USA, 88: 1825-1829, 1991.
24. Katoh, M., Yazaki, Y., Sugimura, T., and Terada, M. c-erbB3 gene encodes secreted as well as transmembrane receptor tyrosine kinase. Biochem. Biophys. Res. Commun., 192: 1189-1197, 1993.
25. Scott, G. K., Robles, R., Park, J. W., Montgomery, P. A., Daniel, J., Holmes, W. E., Lee, J., Keller. G. A., Li, W-L., Fendly, B. M., Wood, W. I., Shepard, H. M., and Benz, C. C. A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells. Mol. Cell. Biol., 13: 2247-2257, 1993.
26. Das, S. K., Tsukamura, H., Paria, B. C., Andrews, G. K., and Dey, S. K. Differential expression of epidermal growth factor receptor (EGF-R) gene and regulation of EGF-R bioactivity by progesterone and estrogen in the adult mouse uterus. Endocrinology, 134: 971-981, 1994.
27. Reiter, J. L., and Maihle, N. J. A 1.8 kb alternative transcript from the human epidermal growth factor receptor gene encodes a truncated form of the receptor. Nucleic Acids Res., 24: 4050-4056, 1996.
28. Tong, B. J., Das, S. K., Threadgill, D., Magnuson, T., and Dey, S. K. Differential expression of the full-length and truncated forms of the epidermal growth factor receptor in the preimplantation mouse uterus and blastocyst. Endocrinology, 137: 1492-1496, 1996.
29. Lee, H., and Maihle, N. J. Isolation and characterization of four alternate c-erbB3 transcripts expressed in ovarian carcinoma derived cell lines and normal human tissues. Oncogene, 16: 3243-3252, 1998.
30. Doherty, J. K., Bond, C., Jardim, A., Adelman, J. P., and Clinton, G. M. The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor. Proc. Natl. Acad. Sci. USA, 96: 10869-10874, 1999.
31. Reiter, J. L., Threadgill, D. W., Eley, G. D., Strunk, K. E., Danielsen, A. J., Sinclair, C. S., Pearsall, R. S., Green, P. J., Yee, D., Lampland, A. L., Balasubramaniam, S., Crossley, T. D., Magnuson, T. R., James, C. D., and Maihle, N. J. Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms. Genomics, 71: 1-20, 2001.
32. Baron, A. T., Lafky, J. M., Connolly, D. C., Peoples, J., O'Kane, D. J., Suman, V. J., Boardman, C. H., Podratz, K. C., and Maihle, N. J. A sandwich type acridinium-linked immunosorbent assay (ALISA) detects soluble ErbB1 (sErbB1) in normal human sera. J. Immunol. Methods, 219: 23-43, 1998.
33. Baron, A. T., Lafky, J. M., Boardman, C. H., Balasubramaniam, S., Suman, V. J., Podratz, K. C., and Maihle, N. J. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer. Cancer Epidemiol. Biomark Prev., 8: 129-137, 1999.
34. Baron, A. T., Lafky, J. M., Suman, V. J., Hillman. D. W., Buenafe, M. C., Boardman, C. H., Podratz, K. C., Perez, E. A., and Maihle, N. J. A preliminary study of serum concentrations of soluble epidermal growth factor receptor (sErbB1), gonadotropins, and steroid hormones in healthy men and women. Cancer Epidemiol. Biomark Prev., 10: 1175-1185, 2001.
35. Gill, G. N., and Weber, W. Purification of functionally active epidermal growth factor receptor protein using a competitive antagonist monoclonal antibody and competitive elution with epidermal growth factor. Methods Enzymol., 146: 82-88, 1987.
36. Baron, A. T., Huntley, B. K., Lafky, J. M., Reiter, J. L., Liebenow, J., McCormick, D. J., Ziesmer, S. C., Roche, P. C., and Maihle, N. J. Monoclonal antibodies specific for peptide epitopes of the epidermal growth factor receptor's extracellular domain. Hybridoma, 16: 259-271, 1997.
37. Malkasian, G. D., Jr., Podratz, K. C., Stanhope, C. R., Ritts, R. E., Jr., and Zurawski, V. R., Jr. CA 125 in gynecologic practice. Am. J. Obstet. Gynecol., 155:515-518, 1986.
38. Niloff, J. M., Knapp, R. C., Lavin, P. T., Malkasian, G. D., Berek, J. S., Mortel, R., Whitney, C., Zurawski, V. R. J., and Bast, R. C. J. The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer. Am. J. Obstet. Gynecol., 155: 56-60, 1986.
39. Zurawski, V. R., Jr., Orjaseter, H., Andersen, A., and Jellum, E. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int. J. Cancer, 42: 677-680, 1988.
40. Talbot, R. W., Jacobsen, D. J., Nagorney, D. M., Malkasian, G. D., and Ritts, R. E., Jr. Temporary elevation of CA 125 after abdominal surgical treatment for benign disease and cancer. Surg. Gynecol. Obstet., 168: 407-412, 1989.
41. Hanley, J. A., and McNeil, B. J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology, 143: 29-36, 1982.
42. Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., Downward, J., Mayes, E. L. V., Whittle, N., Waterfield, M. D., and Seeburg, P. H. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature (Lond.), 309: 418-425, 1984.
43. Salvatori, L., Ravenna, L., Felli, M. P., Cardillo, M. R., Russo, M. A., Frati, L., Gulino, A., and Petrangeli, E. Identification of an estrogen-mediated deoxyribonucleic acid-binding independent transactivation pathway on the epidermal growth factor receptor gene promoter. Endocrinology, 141: 2266-2274, 2000.
44. Yarden, R. I., Lauber, A. H., El-Ashry, D., and Chrysogelos, S. A. Bimodal regulation of epidermal growth factor receptor by estrogen in breast cancer cells. Endocrinol., 137: 2739-2747, 1996.
45. Yarden, R. I., Wilson, M. A., and Chrysogelos, S. A. Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth. J. Cell. Biochem., 36(Suppl): 232-246, 2001.
46. Armstrong, D. G., and Webb, R. Ovarian follicular dominance: the role of intraovarian growth factors and novel proteins. Rev. Reprod., 2: 139-146, 1997.
47. McBean, J. H., Brumsted, J. R., and Stirewalt, W. S. In vivo estrogen regulation of epidermal growth factor receptor in human endometrium. J. Clin. Endocrinol. Metab., 82: 1467-1471, 1997.
48. Granai, C. O., Gajewski, W. H., and Arena, B. Ovarian cancer: issues and management. Cancer J., 7: 7-11, 1994.
49. Harlap, S. The epidemiology of ovarian cancer. In: M. Markman and W. J. Hoskins (eds.), Cancer of the Ovary, pp. 79-93. New York, NY: Raven Press, Ltd., 1993.
50. Meden, H., Marx, D., Fattahi, A., Rath, W., Kron. M., Wuttke, W., Schauer, A., and Kuhn, W. Elevated serum levels of c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy. J. Cancer Res. Clin. Oncol., 129: 378-381, 1994.
51. Meden, H., Marx, D., Schauer, A., Wuttke, W., and Kuhn, W. Prognostic significance of p105 (c-erbB-2. HER2/neu) serum levels in patients with ovarian cancer. Anticancer Res., 17: 757-760, 1997.
52. Cheung, T. H., Wong, Y. F., Chung, T. K. H., Maimonis, P., and Chang, A. M. Z. Clinical use of serum c-erbB-2 in patients with ovarian masses. Gynecol. Obstet. Investig., 48: 133-137, 1999.
53. Yazici, H., Dolapcioglu, K., Buyru, F., and Dalay, N. Utility of c-erbB-2 expression in tissue and sera of ovarian cancer patients. Cancer Investig., 18: 110-114, 2000.
54. Skirnisdottir, I., Sorbe, B., and Seidal, T. The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma. Int. J. Gynecol. Cancer, 11: 119-129, 2001.
55. Cole, P., and Morrison, A. S. Basic issues in population screening for cancer. J. Natl. Cancer Inst., 64: 1263-1272, 1980.
56. Mori, M., and Miyake, H. Dietary and other risk factors of ovarian cancer among elderly women. Jpn. J. Cancer Res., 79: 997-1004, 1988.
57. Risch, H. A., Jain, M., Marrett, L. D., and Howe, G. R. Dietary fat intake and risk of epithelial ovarian cancer. J. Natl. Cancer Inst., 86: 1409-1415, 1994.
58. Glud, E., Kjaer, S. K., Troisi, R., and Brinton, L. A. Fertility drugs and ovarian cancer. Epidemiol. Rev., 20: 237-257, 1998.
59. Kushi, L. H., Mink, P. J., Folsom, A. R., Anderson, K. E., Zheng, W., Lazovich, D., and Sellers, T. A. Prospective study of diet and ovarian cancer. Am. J. Epidemiol., 149: 21-31, 1999.
60. Ness, R. B., Grisso, J. A., Cottreau, C., Klapper, J., Vergona, R., Wheeler, J. E., Morgan, M., and Schlesselman, J. J. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology, 11: 111-117, 2000.
61. Helzlsouer, K. J., Bush, T. L., Alberg, A. J., Bass, K. M., Zacur, H., and Comstock, G. W. Prospective study of serum CA-125 levels as markers of ovarian cancer. JAMA, 269: 1123-1126, 1993.
62. Jacobs, I. J., Skates, S., Davies, A. P., Woolas, R. P., Jeyerajah, A., Weidemann, P., Sibley, K., and Oram, D. H. Risk of diagnosis of ovarian cancer after raised serum ca 125 concentration-a prospective cohort study. Br. Med. J., 313: 1355-1358, 1996.
63. Menon, U., Talaat, A., Jeyarajah, A. R., Rosenthal, A. N., MacDonald N.D., Skates, S. J., Sibley, K., Oram, D. H., and Jacobs, I. J. Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation. Br. J. Cancer, 80: 1644-1647, 1999.
64. Hennekens, C. H., and Buring, J. E. Screening. In: S.L. Mayrent (ed.), Epidemiology in Medicine, pp. 327-347. Boston, MA: Little, Brown and Company, 1987.
65. Pepe, M. S., Etzioni, R., Feng, Z. D., Potter, J. D., Thompson, M. L., Thomquist, M., Winget, M., and Yasui, Y. Phases of biomarker development for early detection of cancer. J. Natl. Cancer Inst., 93: 1054-1061, 2001.
66. Xu, Y., Shen, Z., Wiper, D. W., Wu, M., Morton, R. E., Elson, P., Kennedy, A. W., Belinson, J., Markman, M., and Casey, G. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA, 280: 719-723, 1998.
67. Udagawa, Y., Aoki, D., Ito, K., Uejima, T., Uemura, M., and Nozawa, S. Clinical characteristics of a newly developed ovarian tumour marker, galactosyl-transferase associated with tumour (GAT). Eur. J. Cancer, 34: 489-495, 1998.
68. van Haaften-Day, C., Shen, Y., Xu, F., Yu, Y., Berchuck, A., Havrilesky, L. J., de Bruijn, H. W., van der Zee, A. G., Bast, R. C., Jr., and Hacker, N. F. OVXI, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer (Phila.), 92: 2837-2844, 2001.
69. Mok, S. C., Chao, J., Skates, S., Wong, K-K., Yiu, G. K., Muto, M. G., Berkowitz, R. S., and Cramer, D. W. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J. Natl. Cancer Inst., 93: 1458-1464, 2001.
70. Kim, H., Scorilas, A., Katsaros. D., Yousef, G. M., Massobrio, M., Fracchioli, S., Piccinno, R., Gordini, G., and Diamandis, E. P. Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. Br. J. Cancer, 84: 643-650, 2001.
71. Diamandis, E. P., Okui, A., Mitsui, S., Luo, L. Y., Soosaipillai. A., Grass, L., Nakamura, T., Howarth, D. J., and Yamaguchi, N. Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. Cancer Res., 62: 295-300, 2002.
72. Petricoin, E. F., Ardekani, A. M., Hitt, B. A., Levine, P. J., Fusaro, V. A., Steinberg, S. M., Mills, G. B., Simone, C., Fishman, D. A., Kohn, E. C., and Liotta, L. A. Use of proteomic patterns in serum to identify ovarian cancer. Lancet, 359: 572-577, 2002.
73. Tuxen, M. K., Soletormos, G., and Dombemowsky, P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat. Rev., 21: 215-245, 1995.
74. von Schlippe, M., and Rustin, G. J. Circulating tumour markers in ovarian tumours. Forum Trends in Experimental and Clinical Medicine, 10: 383-392, 2000.
75. Zurawski, V. R., Jr., Broderick, S. F., Pickens, P., Knapp, R. C., and Bast, R. C., Jr. Serum CA 125 levels in a group of nonhospitalized women: relevance for the early detection of ovarian cancer. Obstet. Gynecol., 69: 606-611, 1987.
76. Einhorn, N., Sjovall, K., Knapp, R. C., Hall, P., Scully, R. E., Bast, R. C., Jr., and Zurawski, V. R., Jr. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet. Gynecol., 80: 14-18, 1992.
77. Malkasian, G. D., Jr., Knapp, R. C., Lavin, P. T., Zurawski, V. R., Jr. Podratz, K. C., Stanhope, C. R., Mortel, R., Berek, J. S., Bast, R. C., Jr., and Ritts, R. E. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am. J. Obstet. Gynecol., 159: 341-346, 1988.